Wolverine Trading’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Wolverine Trading’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,900	Closed	-$222K	–	5165
2022 Q4	$222K	Buy	+4,900	New	+$317K	﹤0.01%	3044
2022 Q3	–	Sell	-6,600	Closed	-$444K	–	5570
2022 Q2	$444K	Buy	6,600 +3,000	+83%	+$191K	﹤0.01%	2662
2022 Q1	$300K	Sell	3,600 -1,400	-28%	-$143K	﹤0.01%	3890
2021 Q4	$741K	Buy	5,000 +2,600	+108%	+$404K	﹤0.01%	2969
2021 Q3	$418K	Buy	2,400 +600	+33%	+$96.5K	﹤0.01%	4205
2021 Q2	$292K	Buy	+1,800	New	+$289K	﹤0.01%	4458

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wolverine Trading's MRTX Position: Q1 2022 in Review

Wolverine Trading sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 1,600 shares — an estimated $164K sold.

Wolverine Trading first reported a position in MRTX in Q4 2021 and held it in 1 quarter. The position peaked at $237K in Q4 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

Wolverine Trading reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Wolverine Trading sold 1,600 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $164K.
Wolverine Trading first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
Wolverine Trading's Mirati Therapeutics, Inc. Common Stock position peaked at $237K in Q4 2021.
253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Wolverine Trading's 13F filing for Q1 2022, filed 16 May 2022.